Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Inflamm Bowel Dis. 2011 Oct 12;18(6):1081–1091. doi: 10.1002/ibd.21898

Figure 2. Rolipram decreases enterocyte migration.

Figure 2

(A) Colonic damage was induced by administration of 3.5% Dextran Sodium Sulfate (DSS) for 5 days in drinking water followed by rolipram treatment for 5 days. (B) Wound-associated epithelium (Arrows) was reduced in animals that received rolipram during the recovery phase after DSS damage. Animals received either DSS, DSS followed by rolipram treatment, or rolipram alone. After the tenth day animals were sacrificed and damage assessed histologically. (C) Quantification of actively healing ulcers at day 10 following treatment. *, P≤0.05 compared to DSS alone. While the total number of ulcers was similar between animals that received DSS and those that received DSS and rolipram in combination, DSS/rolipram resulted in the significant increase in ulcers that remained unhealed (actively healing ulcers). (D) Quantification of the length of the wound-associated epithelium (WAE) at day 10. *, P≤0.05 compared to DSS alone. Values are mean±SEM, (n=4).